{
  "id": "oncolytic-virus-therapy",
  "title": "Oncolytic Virus Therapy",
  "lang": "en",
  "source_lang": "en",
  "summary": "Oncolytic virus therapy uses viruses that preferentially infect tumors to destroy cancer cells and stimulate antitumor immunity.",
  "category": "health",
  "subcategory": "medicine",
  "type": "concept",
  "aliases": [
    "Oncolytic virotherapy",
    "Oncolytic viral therapy",
    "Virotherapy for cancer"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/oncolytic-virus-therapy/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/oncolytic-virus-therapy/",
      "json": "https://aiwiki.page/zh/oncolytic-virus-therapy.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Oncolytic virus therapy is a form of cancer treatment that uses viruses capable of preferentially infecting and killing malignant cells. These viruses may occur naturally or be genetically modified to improve tumor selectivity, reduce pathogenicity, or produce therapeutic molecules. Their activity combines direct destruction of infected cells with changes in the tumor environment that can promote an immune response against cancer. This dual action places the field at the intersection of virology, gene therapy, and cancer immunotherapy.\n\nThe clinical importance of oncolytic viruses lies partly in their potential to make poorly inflamed tumors more recognizable to the immune system. However, activity demonstrated in laboratory models has not consistently translated into improved survival in clinical trials. A small number of products have received regulatory authorization for specific indications, while many other viruses, delivery methods, and combination regimens remain experimental. Evidence therefore has to be interpreted for each product, cancer type, route of administration, and treatment setting rather than for oncolytic viruses as a single interchangeable class."
    },
    {
      "heading": "Historical development and clinical emergence",
      "text": "The idea of using infection against cancer predates molecular virology. During the nineteenth and early twentieth centuries, physicians occasionally reported tumor regression during naturally acquired infections. Such observations were difficult to interpret: diagnoses were less precise than modern standards, infections were uncontrolled, and apparent regressions were often temporary. Nevertheless, they suggested that an infectious process could alter tumor growth through direct cellular damage, immune activation, or both.\n\nMid-twentieth-century investigators deliberately administered several viruses to patients with advanced cancer, including hepatitis-associated agents, adenoviruses, and other naturally occurring viruses. These studies generally lacked the controls, manufacturing standards, and molecular characterization expected of modern clinical trials. Antiviral immunity frequently limited infection, while pathogenicity restricted the doses that could be given. The inability to distinguish reliably between infection of tumors and infection of normal tissues was a central obstacle.\n\nRecombinant DNA technology changed the field by allowing investigators to remove viral virulence genes or make replication dependent on features of malignant cells. In 1991, Robert Martuza and colleagues reported an engineered herpes simplex virus with an inactivated thymidine kinase gene that inhibited experimental human glioma growth. Subsequent herpesvirus designs targeted additional genes involved in neurovirulence. In parallel, adenovirus research produced ONYX-015, an E1B-55K-deleted virus that entered clinical development during the 1990s. These programs established practical frameworks for genetic attenuation, tumor injection, viral monitoring, and early-phase safety assessment.\n\nRegulatory milestones followed different national pathways. China approved H101, marketed as Oncorine, in 2005 for use with chemotherapy in a specified head-and-neck cancer setting. In 2015, the United States Food and Drug Administration approved talimogene laherparepvec, commonly abbreviated T-VEC, for local treatment of unresectable cutaneous, subcutaneous, and nodal melanoma lesions recurrent after initial surgery. European authorization followed that year with a differently defined melanoma indication. Japan granted conditional and time-limited approval to teserpaturev, or G47Δ, for malignant glioma in 2021. These decisions did not establish a general indication for viral treatment of all cancers; each concerned a particular product and a narrowly defined clinical context."
    },
    {
      "heading": "Tumor selectivity and direct destruction of cancer cells",
      "text": "An oncolytic virus must enter a susceptible cell, express viral genes, and exploit cellular machinery sufficiently to damage the cell or generate infectious progeny. In productive infection, newly formed virus particles can spread to neighboring cells, amplifying the initial inoculum. Cancer cells can be especially permissive because malignant transformation alters antiviral defenses, growth signaling, metabolism, and cell-death pathways. Yet these alterations vary widely between tumors and even between neighboring cells within one tumor.\n\nOne important determinant is the interferon response. Normal cells detect viral nucleic acids and activate signaling pathways that restrict viral replication and warn surrounding cells. Some cancers have defects in these pathways, making them less able to suppress infection. Other tumors retain strong antiviral responses and resist viruses despite carrying many cancer-associated alterations. Tumor selectivity is therefore relative rather than absolute: a virus may replicate more efficiently in malignant tissue without being completely incapable of infecting normal cells.\n\nEngineered selectivity can operate at several stages. Viral entry proteins can be modified to recognize receptors enriched on cancer cells. Genes needed for efficient replication in resting normal cells can be deleted, leaving the virus more dependent on the nucleotide supply or growth-associated functions of proliferating cells. Tumor-associated promoters can control essential viral genes, while sequences recognized by tissue-specific microRNAs can suppress replication in selected normal organs. These strategies alter different biological checkpoints and cannot be assumed to provide equivalent protection.\n\nA historically important example is deletion of adenoviral E1B-55K. ONYX-015 was initially described as selectively replicating in cells with defective p53 function because E1B-55K participates in counteracting p53-mediated responses. Later work showed that the biology was more complex, including effects on viral late messenger RNA export and other cellular functions. Thus, p53 status alone does not adequately explain or predict the selectivity of these viruses.\n\nDirect killing can involve membrane disruption, apoptosis, and other forms of regulated or uncontrolled cell death. Viral replication may also damage tumor-associated blood vessels or expose nearby malignant cells to inflammatory mediators. Nevertheless, infection rarely spreads uniformly through an entire human tumor. Dense tissue architecture, poor perfusion, antiviral responses, and resistant cellular subpopulations can interrupt propagation. The distinction between killing infected cells and controlling the whole cancer is fundamental to interpreting laboratory and clinical results."
    },
    {
      "heading": "Antitumor immunity and the tumor microenvironment",
      "text": "The immune consequences of viral infection extend beyond the cells that support replication. Infected and dying cancer cells release tumor antigens alongside viral molecules and cellular danger signals. These signals can activate antigen-presenting cells, particularly dendritic cells, which process proteins and present peptide fragments to lymphocytes. If this process generates an effective response, T cells may recognize malignant cells elsewhere in the body, including cells that were never infected by the therapeutic virus.\n\nThis mechanism is often described as an in situ vaccination effect. Unlike a conventional vaccine prepared around a predetermined antigen, the infected tumor supplies a mixture of antigens from the individual cancer. Some may arise from cancer-associated mutations, while others are shared with normal tissues. Effective immunity requires more than antigen release: antigen-presenting cells must receive appropriate activation signals, tumor-reactive lymphocytes must expand, and those cells must reach and function within tumor deposits.\n\nThe tumor microenvironment can obstruct each step. Abnormal blood vessels restrict immune-cell entry; stromal cells and extracellular matrix create physical barriers; regulatory lymphocytes and suppressive myeloid cells inhibit effector activity. Nutrient depletion, low oxygen, and inhibitory receptor signaling further limit immune function. Viral infection may counter some of these conditions by inducing inflammatory cytokines and chemokines, but it may also trigger compensatory inhibitory pathways. For example, interferon signaling can increase expression of PD-L1, a ligand that suppresses activated T cells through the PD-1 checkpoint.\n\nEngineered viruses can carry immune-stimulatory genes intended to strengthen this process. T-VEC expresses human granulocyte–macrophage colony-stimulating factor, or GM-CSF, which can support recruitment and differentiation of antigen-presenting cells. Other experimental constructs encode interleukins, chemokines, checkpoint-blocking proteins, or molecules that redirect immune cells toward cancer. Local production is intended to concentrate biological activity within tumors, although locally expressed proteins can still enter the circulation and produce systemic effects.\n\nAntiviral and antitumor immunity are not identical. Rapid elimination of the virus can reduce tumor infection, whereas insufficient antiviral control can create safety problems. An immune response dominated by viral antigens may not generate durable recognition of cancer antigens. This tension helps explain why stronger viral replication, greater inflammation, and better cancer control do not always occur together. Immune activation is a plausible mechanism and a measurable biological event, but neither alone establishes clinical benefit."
    },
    {
      "heading": "Viral platforms and genetic design",
      "text": "Several unrelated virus families have been developed as therapeutic platforms. Their genomes, natural host ranges, cellular entry mechanisms, and susceptibility to antiviral defenses differ substantially. Large DNA viruses generally offer room for multiple inserted genes, whereas many RNA viruses replicate rapidly but accommodate smaller genetic payloads. No platform is intrinsically best for every cancer, and design choices often involve trade-offs between replication, selectivity, manufacturability, and immune stimulation.\n\nHerpes simplex virus type 1 is a prominent platform because its large genome permits extensive engineering and because clinically available drugs can inhibit susceptible strains. T-VEC has deletions affecting the ICP34.5 neurovirulence genes and the ICP47 gene, together with insertion of the human GM-CSF gene. Deleting ICP34.5 reduces the virus’s ability to overcome certain antiviral defenses in normal tissue. ICP47 deletion relieves inhibition of antigen presentation and also affects expression of the neighboring viral US11 gene. These changes are biologically interconnected rather than independent switches. The platform retains a relationship to herpes simplex biology, including the potential for herpetic infection.\n\nAdenoviruses are non-enveloped DNA viruses whose entry proteins, early replication genes, and transcriptional control elements can be modified. H101 and ONYX-015 are related examples involving E1B-55K deletion, although they are not identical products. Other adenoviruses use tumor-associated promoters or deletions affecting interactions with the retinoblastoma pathway. Vaccinia viruses offer another large-genome platform, with substantial capacity for transgenes and a history of production associated with smallpox vaccination. Their broad cellular tropism makes engineered attenuation and control of off-target replication particularly important.\n\nRNA-virus platforms include reovirus, measles virus, vesicular stomatitis virus, Newcastle disease virus, poliovirus-derived constructs, and coxsackievirus. Pelareorep is an investigational reovirus formulation. Some attenuated measles viruses exploit high expression of entry receptors on particular cancers, while poliovirus-derived constructs use engineered sequences intended to reduce neurovirulence while preserving tumor infection. Natural preference for transformed cells may contribute to activity, but it does not remove the need for product-specific safety testing.\n\nAdditional design elements can insert enzymes that activate prodrugs, proteins that disrupt tumor matrix, or binding molecules that recruit immune cells. Each addition increases biological complexity. A payload may weaken viral fitness, alter tissue distribution, or change immune toxicity. The relevant therapeutic product is therefore the complete engineered virus—including its backbone, inserted genes, production history, and formulation—not simply the name of the parental virus family."
    },
    {
      "heading": "Administration, distribution, and barriers to delivery",
      "text": "Delivery is a major determinant of whether an oncolytic virus can reach enough cancer cells to matter clinically. Direct intratumoral injection deposits virus into an accessible lesion and reduces some of the losses associated with circulation. It also allows repeat sampling and observation of local effects. Its limitations include uneven distribution within the injected mass and difficulty reaching small, numerous, deep, or anatomically hazardous lesions. Ultrasound or computed tomography can guide injections into selected internal tumors, but procedural access remains distinct from biological susceptibility.\n\nT-VEC illustrates a local delivery strategy. It is injected into visible, palpable, or ultrasound-detectable melanoma lesions, using a lower-concentration first treatment followed by higher-concentration treatments. Not every lesion can necessarily be treated at each visit because both injection volume and anatomical access are limited. Regression in an injected lesion can reflect direct infection and local inflammation; regression in a non-injected lesion is compatible with systemic immune activity but does not by itself prove which mechanism caused the response.\n\nIntravenous administration potentially reaches multiple metastatic sites, but circulating virus encounters dilution, antibodies, complement, blood cells, and uptake by organs such as the liver and spleen. Pre-existing neutralizing antibodies may arise from natural infection or previous vaccination, while treatment itself commonly induces additional antiviral immunity. The effect is platform-dependent: antibodies can hinder delivery without necessarily abolishing all biological activity. Viral genomes detected in blood establish exposure, not successful replication inside a tumor.\n\nAfter leaving the circulation, viruses face abnormal tumor vasculature, high interstitial pressure, extracellular matrix, and poorly connected tissue spaces. These obstacles are particularly relevant to fibrotic tumors such as some forms of pancreatic cancer. In brain tumors, vascular barriers and the consequences of local inflammation create additional constraints. Direct injection or delivery into a surgical cavity can bypass parts of the blood–brain barrier, but neither guarantees uniform distribution through infiltrating tumor.\n\nExperimental delivery approaches include regional arterial infusion, administration into body cavities, repeated dosing schedules, protective coatings, and use of cells as carriers. Mesenchymal stromal cells or immune cells have been investigated as vehicles that might shield virus during transit. These methods raise further questions about release, targeting, reproducibility, and safety. Successful delivery has to be demonstrated through tissue analysis and clinical outcomes rather than inferred solely from the route of administration."
    },
    {
      "heading": "Approved uses and interpretation of clinical evidence",
      "text": "The clearest distinction in clinical assessment is between biological activity, tumor response, and demonstrated patient benefit. Viral replication, immune-cell infiltration, or shrinkage of an injected lesion can establish activity without showing longer survival or improved quality of life. Likewise, an encouraging uncontrolled study cannot determine how much benefit results from the virus rather than patient selection, accompanying treatment, or the natural course of disease. Regulatory conclusions therefore depend heavily on study design, endpoints, and the availability of alternative treatments.\n\nT-VEC was evaluated in OPTiM, a phase III randomized controlled trial involving 436 patients with unresectable stage IIIB–IV melanoma. Participants received intralesional T-VEC or subcutaneous GM-CSF. The primary endpoint was a durable response lasting continuously for at least six months and beginning within the first twelve months. Durable response occurred in 16.3% of the T-VEC group and 2.1% of the control group; overall response rates were 26.4% and 5.7%, respectively. The trial supported efficacy in a selected population with injectable disease, but its comparator was not a contemporary checkpoint-inhibitor regimen.\n\nThe United States prescribing indication for T-VEC concerns local treatment of qualifying melanoma lesions. Its labeling states that it has not been shown to improve overall survival or to affect visceral metastases. These limitations matter because melanoma may involve both accessible skin lesions and clinically important internal disease. European authorization specified a population without bone, brain, lung, or other visceral disease. A product’s approval in one jurisdiction therefore should not be read as evidence for broader use in every jurisdiction or disease stage.\n\nH101 received Chinese approval in combination with chemotherapy for a specified head-and-neck cancer indication, with clinical development including nasopharyngeal carcinoma. That authorization does not establish efficacy for all adenoviral constructs or all solid tumors. Teserpaturev received Japanese conditional and time-limited approval for malignant glioma after a small, single-arm phase II study involving 19 patients with residual or recurrent glioblastoma. The absence of a randomized concurrent control limits causal interpretation, particularly in a disease where eligibility, prior treatment, and subsequent care strongly influence outcomes.\n\nNegative studies are equally informative. A phase III trial of T-VEC combined with pembrolizumab in advanced melanoma did not significantly improve its primary progression-free survival or overall survival endpoints over pembrolizumab with placebo. The PHOCUS phase III study of pexastimogene devacirepvec followed by sorafenib in advanced hepatocellular carcinoma was stopped for futility. Such results show that a plausible immune mechanism and early response signals do not reliably predict success in larger comparative trials."
    },
    {
      "heading": "Combination treatment and determinants of response",
      "text": "Combination therapy seeks to address barriers that a virus alone may not overcome. The most extensively explored partners include immune checkpoint inhibitors, chemotherapy, radiation therapy, and selected targeted drugs. The intended interaction depends on the combination: one treatment may improve viral replication, increase tumor-antigen release, facilitate immune-cell entry, or prevent suppression of newly activated lymphocytes. A favorable laboratory interaction, however, may disappear at clinically tolerable doses or in a different treatment sequence.\n\nCheckpoint blockade provides a clear mechanistic rationale. Viral infection can attract T cells and induce interferon-associated inflammation, while antibodies against PD-1, PD-L1, or CTLA-4 can reduce inhibitory signaling. Early studies of some combinations showed increased response rates or encouraging tissue changes. The negative phase III T-VEC–pembrolizumab result nevertheless demonstrates that making a tumor more inflamed does not automatically improve survival beyond an already effective immunotherapy. Other combinations require their own controlled evaluation rather than extrapolation from that trial or from a shared mechanism.\n\nChemotherapy and radiation can increase antigen release and alter the tumor environment, but they can also suppress immune cells required for an antitumor response. Some drugs inhibit cellular pathways used by the virus; others create conditions more favorable for replication. Timing therefore matters. Giving an immune-suppressive treatment before viral administration might prolong viral persistence while simultaneously weakening subsequent immune priming. Giving it later could have a different effect. These competing mechanisms complicate the interpretation of combination studies.\n\nInvestigational approaches also pair viruses with CAR T-cell therapy, other adoptive cell therapies, or multispecific immune-engaging proteins. Viruses can be engineered to produce chemokines that attract transferred cells or to express an artificial target on infected tumor cells. The latter strategy could, in principle, broaden recognition beyond naturally occurring cancer antigens. Its limitations include incomplete infection, heterogeneous target expression, potential normal-tissue exposure, and the complexity of controlling two biologically active treatments.\n\nNo broadly validated biomarker identifies patients likely to benefit across all oncolytic-virus platforms. Candidate predictors include viral entry receptors, interferon-pathway activity, baseline immune infiltration, tumor burden, anatomical accessibility, and neutralizing-antibody levels. Measurements may have different implications for different viruses: a strong antiviral state can impede replication, yet an intact immune system may be necessary for durable tumor control. Biomarkers also change during treatment, making the timing and location of a biopsy important to interpretation."
    },
    {
      "heading": "Adverse effects, transmission, and clinical monitoring",
      "text": "The safety profile of an oncolytic virus reflects its parental virus, engineered modifications, administration route, dose, and host. Common reactions in trials of intratumoral products include injection-site discomfort, fever, chills, fatigue, and influenza-like symptoms. These findings often reflect local tissue injury or systemic inflammatory signaling rather than uncontrolled infection. They nevertheless require distinction from bacterial infection, progression of the underlying cancer, or adverse effects of accompanying treatments.\n\nReplication-competent products create risks that do not arise with ordinary noninfectious medicines. T-VEC can cause herpetic infection, including serious disseminated infection in susceptible individuals. Its United States labeling contraindicates use in immunocompromised and pregnant patients. Immunosuppression may result from an underlying disorder, transplantation, or medication, and its significance depends on both degree and mechanism. Attenuation reduces pathogenic potential but does not make a live therapeutic virus biologically inert.\n\nExposure of other people is a separate safety issue. Viral material may be present at injection sites, in dressings, or in bodily fluids, depending on the product and route. Product-specific procedures address protective equipment, lesion covering, dressing disposal, accidental needlestick injury, and exposure of close contacts. For herpesvirus products, susceptible household members and health-care workers are relevant to risk assessment. These precautions derive from the behavior of the actual therapeutic virus rather than from a general assumption that all oncolytic viruses transmit in the same way.\n\nShedding studies require careful interpretation. A positive polymerase chain reaction test detects viral genetic material, which may come from inactive particles or residual genomes. It does not necessarily establish the presence of infectious virus or the likelihood of person-to-person transmission. Culture-based infectivity assays provide different information, although they also have sampling and sensitivity limitations. Conversely, a negative result from one specimen cannot establish absence from all tissues or at all times.\n\nInflammation can produce site-specific hazards. Swelling within the central nervous system may have serious consequences because of limited space, while ulceration or necrosis in superficial tumors can complicate wound care. Severe systemic inflammatory events, including cytokine release syndrome, have been reported with some investigational platforms and regimens. Availability of an active antiviral drug can provide a rescue option for certain susceptible viruses, but this is not universal and may also terminate therapeutic viral activity."
    },
    {
      "heading": "Manufacturing, trial assessment, and unresolved challenges",
      "text": "An oncolytic virus is a living biological product whose performance depends on more than its nominal genome sequence. Manufacturing must control the identity of the production cell substrate, genetic stability of the virus, residual host-cell material, adventitious agents, purity, and infectious potency. Serial propagation can select variants with altered growth properties. A process that produces large amounts of viral genetic material may still yield insufficient infectious virus, making the choice of potency assay central to batch consistency.\n\nDose units are platform-specific. Plaque-forming units, infectious units, and total particle counts describe related but nonidentical quantities. Two preparations with the same particle count can have different infectivity, and assays performed in different cell systems may not be directly comparable. Large-scale purification, freezing, thawing, transport, and storage can affect enveloped and non-enveloped viruses differently. These practical constraints influence which platforms can be manufactured reproducibly and delivered across a health system.\n\nClinical assessment also requires methods suited to a treatment that can generate inflammation and delayed responses. Apparent tumor enlargement may represent progression, immune infiltration, tissue necrosis, or a mixture. Immune-response criteria can allow confirmation of suspected progression in appropriate trial settings, but true progression remains common. Separate measurement of injected and non-injected lesions helps distinguish local control from broader activity. For brain tumors, interpretation of magnetic resonance imaging is further complicated by treatment-related enhancement, edema, and corticosteroid exposure.\n\nMechanistic studies increasingly combine serial biopsies, blood measurements, viral sequencing, and immune profiling. Detection of viral genomes does not prove replication; stronger evidence may include expression of replication-associated viral products, recovery of infectious progeny, and appropriate temporal changes. Similarly, increased lymphocyte infiltration does not establish that those cells recognize tumor antigens rather than viral antigens. Correlative studies are most informative when embedded in trials capable of testing clinical benefit rather than treated as substitutes for those trials.\n\nPersistent challenges include reaching disseminated disease, maintaining selectivity without losing potency, overcoming heterogeneous resistance, and identifying combinations that improve meaningful outcomes. Trials must also distinguish a novel virus’s contribution from that of an active accompanying drug. Randomized comparisons, prespecified endpoints, adequate follow-up, and systematic pharmacovigilance are particularly important when early studies involve small, highly selected populations. For conditional approvals and accelerated development pathways, confirmatory evidence is essential to determine whether initial response signals translate into durable benefit in the authorized population."
    }
  ],
  "links": [
    "cancer",
    "gene-therapy",
    "cancer-immunotherapy",
    "immune-system",
    "clinical-trial",
    "dna",
    "chemotherapy",
    "surgery",
    "interferon",
    "dendritic-cell",
    "t-cell",
    "vaccine",
    "mutation",
    "cytokine",
    "herpes-simplex",
    "smallpox",
    "x-ray-computed-tomography",
    "antibody",
    "pancreatic-cancer",
    "brain",
    "blood-brain-barrier",
    "quality-of-life",
    "randomized-controlled-trial",
    "immune-checkpoint-inhibitor",
    "radiation-therapy",
    "ctla-four",
    "car-t-cell-therapy",
    "adoptive-cell-therapy",
    "biomarker",
    "biopsy",
    "fever",
    "immunosuppression",
    "central-nervous-system",
    "cytokine-release-syndrome",
    "antiviral-drug",
    "health-system",
    "magnetic-resonance-imaging",
    "pharmacovigilance"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}